Double Pfizer jab will keep adolescents out of hospital
A new study from the Centres for Disease Control and Prevention (CDC) shows that two doses of the Pfizer-BioNTech COVID-19 vaccine were highly effective in preventing hospitalisation among adolescents aged between 12 and 17.
The clinical trial showed that the vaccine was effective in preventing COVID-19. However, researchers wanted to look at the effectiveness of the Pfizer vaccine in preventing hospitalisation among adolescents. The control case study included patients aged 12 to 18 years admitted to paediatric hospitals.
The study took place from June to September 2021. It included 572 eligible patients. Various reasons led to the exclusion of 108 patients. At least 56 were partially vaccinated or had their second dose between zero and 13 days before getting sick.
Among the 464 hospitalised adolescents (179 case-patients and 285 controls) the average age was 15 years. At least 72% had at least one underlying condition, including obesity, and 68% attended in-person school. The two-dose vaccine was 93% effective against COVID-19 hospitalisation. This proved the vaccine was highly effective at preventing COVID-19 hospitalisation ion this age group. The Delta variant was predominant then.
Younger kids well-protected
According to the Food and Drug Administration (FDA), a trial of about 2250 children showed the Pfizer vaccine prevented 90.7% of symptomatic cases in children aged five to 11. Vaccinated children experienced milder symptoms and none developed fevers. The side effects were consistent with previous observations.
Vaccination opened for South African teenagers last Wednesday, and over 35 000 children got vaccinated by Friday, the highest within 72 hours. The government wants to vaccinate at least 6 million children within this age group. However, South Africa is giving this cohort just one dose of the vaccine. – Health-e News
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Double Pfizer jab will keep adolescents out of hospital
by Nompilo Gwala, Health-e News
October 26, 2021